



GLAND PHARMA LIMITED

May 31, 2022

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra
(East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Disclosure of Related Party Transactions for the half-year ended March 31, 2022

In Compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the details on Related Party Transactions for the half-year ended March 31, 2022, prepared in accordance with the format specified by SEBI vide circular SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021.

This is for your information and records.

Yours truly,

For Gland Pharma Limited



Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer

Regd. Office:

Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads
D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal
Medchal-Malkajgiri District, Hyderabad 500043, Telangana, India
Tel: +91-40-30510999 Fax: +91-40-30510800

Corporate Office:

Plot No. 11 & 84, TSIC Phase: IV
Pashamylaram (V), Patancheru (M), Sangareddy District
Hyderabad 502307, Telangana, India
Tel: +91-8455-699999

GLAND PHARMA LIMITED

Disclosure of related party transactions for the half-year ended March 31, 2022

(Rs. In million)

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S.No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (As at September 30, 2021)	Closing balance (As at March 31, 2022)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
1	Gland Pharma Limited		Gland Pharma International Pte Ltd.		Subsidiary	Investment in equity shares	750.00	76.08	-	-	-	-	-	-	-	-	Business purpose
2	Gland Pharma Limited		Avanc Pharma Distribution Co., Ltd.		Fellow subsidiary	Sale of service	10.00	7.17	(7.16)	-	-	-	-	-	-	-	-
3	Gland Pharma Limited		Avanc Pharmaceutical Co., Ltd.		Fellow subsidiary	Sale of service	19.16	0.72	(0.72)	-	-	-	-	-	-	-	-
4	Gland Pharma Limited		Fosun Pharma USA Inc.		Fellow subsidiary	Advance for supply of goods	-	-	(7.49)	-	-	-	-	-	-	-	-
5	Gland Pharma Limited		Fosun Pharma USA Inc.		Fellow subsidiary	Sale of goods	1,261.65	651.30	433.02	353.89	-	-	-	-	-	-	-
6	Gland Pharma Limited		Fosun Pharma USA Inc.		Fellow subsidiary	Sale of service	244.50	0.68	43.00	-	-	-	-	-	-	-	-
7	Gland Pharma Limited		Fosun Pharma USA Inc.		Fellow subsidiary	Reimbursement of expense	54.08	53.40	-	-	-	-	-	-	-	-	-
8	Gland Pharma Limited		Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.		Fellow subsidiary	Reimbursement of expense	0.88	0.88	0.49	0.50	-	-	-	-	-	-	-
9	Gland Pharma Limited		Tridem Pharma SAS		Fellow subsidiary	Sale of goods	1,500.00	330.47	42.34	10.15	-	-	-	-	-	-	-
10	Gland Pharma Limited		Wanbang Biopharmaceutical Company Limited		Fellow subsidiary	Purchase of raw material	2,250.00	488.73	(113.82)	328.65	-	-	-	-	-	-	-
11	Gland Pharma Limited		Srinivas Sadu		Key management personnel	Remuneration	116.06	88.67	(6.21)	(2.59)	-	-	-	-	-	-	-
12	Gland Pharma Limited		Srinivas Sadu		Key management personnel	Employee stock option compensation expense	7.52	3.81	-	-	-	-	-	-	-	-	-
13	Gland Pharma Limited		Ravi Shekhar Mitra		Key management personnel	Remuneration	15.15	8.73	(1.42)	(0.70)	-	-	-	-	-	-	-
14	Gland Pharma Limited		Satyanarayana Murthy Chavali		Key management personnel	Sitting fee	0.50	0.30	-	-	-	-	-	-	-	-	-
15	Gland Pharma Limited		Satyanarayana Murthy Chavali		Key management personnel	Commission	2.50	1.25	(1.25)	(2.25)	-	-	-	-	-	-	-
16	Gland Pharma Limited		Yiu Kwan Stanley Lau		Key management personnel	Sitting fee	0.40	0.20	-	(0.14)	-	-	-	-	-	-	-
17	Gland Pharma Limited		Yiu Kwan Stanley Lau		Key management personnel	Commission	4.57	2.33	(2.24)	(3.14)	-	-	-	-	-	-	-
18	Gland Pharma Limited		Udo J. Vetter		Key management personnel	Sitting fee	0.40	0.20	-	-	-	-	-	-	-	-	-
19	Gland Pharma Limited		Udo J. Vetter		Key management personnel	Commission	2.50	1.25	(1.25)	(1.72)	-	-	-	-	-	-	-
20	Gland Pharma Limited		Essaji Goolam Vahanvati		Key management personnel	Sitting fee	0.40	0.30	-	-	-	-	-	-	-	-	-
21	Gland Pharma Limited		Essaji Goolam Vahanvati		Key management personnel	Commission	2.50	1.25	(1.25)	(2.25)	-	-	-	-	-	-	-
22	Gland Pharma Limited		Nainalal Kidwai		Key management personnel	Sitting fee	0.40	0.30	-	-	-	-	-	-	-	-	-
23	Gland Pharma Limited		Nainalal Kidwai		Key management personnel	Commission	10.00	5.00	(5.00)	(9.00)	-	-	-	-	-	-	-
24	Gland Pharma Limited		P. Sampath Kumar		Key management personnel	Remuneration	4.61	2.40	(0.41)	(0.15)	-	-	-	-	-	-	-
25	Gland Pharma Limited		P. Sampath Kumar		Key management personnel	Employee stock option compensation expense	0.50	0.25	-	-	-	-	-	-	-	-	-
	Total						6,258.28	1,725.67	370.63	663.76							

Notes

- Amount in bracket denotes credit balance.
- The value of transactions approved, in case of omnibus approval granted by the Audit Committee, are for the financial year 2021-22.
- PAN details are not included in the above format as per the guidance note for related party transactions dated April 25, 2022, issued by the Stock exchanges.
- All above transactions are in the ordinary course of business and on arms' length basis. All outstanding balances are to be settled in cash and are unsecured.
- No Specific financial indebtedness was incurred for making investment in the wholly owned subsidiary.
- The remuneration to key managerial person does not include the provision made for gratuity and compensated absences, as they are on actuarial basis for the Company as a whole.